This prespecified secondary analysis of ATTRibute-CM quantifies acoramidis's patient-reported health status benefit in transthyretin amyloid cardiomyopathy, complementing its established mortality and hospitalization reductions.
Acoramidis significantly improves quality of life for ATTR-CM patients.
Acoramidis offers a new potential treatment option for improving heart failure-related health outcomes in transthyretin amyloid cardiomyopathy (ATTR-CM) patients. Acoramidis showed a significant improvement in Kansas City Cardiomyopathy Questionnaire Overall Summary scores with a least-squares mean difference of 9.9 points compared to placebo at 30 months. These findings highlight acoramidis' impact on patient-reported outcomes, suggesting it may alter disease progression in ATTR-CM. The study is robust, indicating meaningful clinical benefit. Acoramidis substantially improves heart failure health status in ATTR-CM patients, suggesting it modifies disease progression.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Sherrod CF 4th, Fontana M, Gillmore JD, Kastritis E, Mitchell JD, Krejci J, Tauras JM, van der Meer P, Chen C, Falvey H, Siddhanti S, Tamby JF, Fox JC, Cappelli F, Masri A, Garcia-Pavia P, Hanna M, Sperry BW
Citation:Sherrod CF 4th, Fontana M, Gillmore JD, et al. Effect of Acoramidis on Heart Failure-Related Health Status: A Secondary Analysis of the ATTRibute-CM Randomized Clinical Trial. JAMA cardiology. 2026;11(9):857-866. doi:10.1001/jamacardio.2026.2413